A federal vaccine panel said Tuesday the benefits of the Pfizer-BioNTech COVID-19 vaccine for children ages 5-11 years outweigh the potential risks, although some expressed hesitation in recommending it for all children in this age group.
Members of the Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee said they want to protect children from COVID-related infections, hospitalizations and deaths as well as disruptions to their education. However, the risk of myocarditis, though rare, gave some pause.
Source: American Academy of Pediatrics
https://www.aappublications.org/news/2021/10/26/fda-pfizer-covid-vaccine-children-102621
